Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis

OBJECTIVES: To evaluate the safety and immunogenicity of third and fourth BNT162b2 boosters in patients with SLE and rheumatoid arthritis (RA). METHODS: Patients with SLE and RA aged 18–65 years who completed a series of inactivated, adenoviral vector, or heterogenous adenoviral vector/mRNA vaccines...

Descripción completa

Detalles Bibliográficos
Autores principales: Assawasaksakul, Theerada, Sathitratanacheewin, Seelwan, Vichaiwattana, Preeyaporn, Wanlapakorn, Nasamon, Poovorawan, Yong, Avihingsanon, Yingyos, Assawasaksakul, Nawaporn, Kittanamongkolchai, Wonngarm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Epidemiology and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340581/
https://www.ncbi.nlm.nih.gov/pubmed/35902168
http://dx.doi.org/10.1136/lupus-2022-000726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340581/
https://www.ncbi.nlm.nih.gov/pubmed/35902168
http://dx.doi.org/10.1136/lupus-2022-000726

Ejemplares similares